Canada · Delayed Price · Currency is CAD BioSyent Statistics
Total Valuation
BioSyent has a market cap or net worth of CAD 126.24 million. The enterprise value is 106.82 million.
| Market Cap | 126.24M |
| Enterprise Value | 106.82M |
Important Dates
The next estimated earnings date is Thursday, November 20, 2025.
| Earnings Date | Nov 20, 2025 |
| Ex-Dividend Date | Aug 29, 2025 |
Share Statistics
BioSyent has 11.26 million shares outstanding. The number of shares has decreased by -2.47% in one year.
| Current Share Class | 11.26M |
| Shares Outstanding | 11.26M |
| Shares Change (YoY) | -2.47% |
| Shares Change (QoQ) | -0.15% |
| Owned by Insiders (%) | 14.06% |
| Owned by Institutions (%) | 19.49% |
| Float | 8.59M |
Valuation Ratios
The trailing PE ratio is 15.80 and the forward PE ratio is 13.93.
| PE Ratio | 15.80 |
| Forward PE | 13.93 |
| PS Ratio | 3.20 |
| PB Ratio | 3.36 |
| P/TBV Ratio | 3.84 |
| P/FCF Ratio | 10.60 |
| P/OCF Ratio | 10.55 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.44, with an EV/FCF ratio of 8.97.
| EV / Earnings | 12.93 |
| EV / Sales | 2.70 |
| EV / EBITDA | 9.44 |
| EV / EBIT | 9.98 |
| EV / FCF | 8.97 |
Financial Position
The company has a current ratio of 6.07, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.07 |
| Quick Ratio | 5.00 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | 0.08 |
| Debt / FCF | 0.08 |
| Interest Coverage | 197.21 |
Financial Efficiency
Return on equity (ROE) is 22.62% and return on invested capital (ROIC) is 17.82%.
| Return on Equity (ROE) | 22.62% |
| Return on Assets (ROA) | 15.75% |
| Return on Invested Capital (ROIC) | 17.82% |
| Return on Capital Employed (ROCE) | 27.84% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.93 |
| Inventory Turnover | 1.58 |
Taxes
In the past 12 months, BioSyent has paid 2.87 million in taxes.
| Income Tax | 2.87M |
| Effective Tax Rate | 25.78% |
Stock Price Statistics
The stock price has increased by +0.09% in the last 52 weeks. The beta is 0.32, so BioSyent's price volatility has been lower than the market average.
| Beta (5Y) | 0.32 |
| 52-Week Price Change | +0.09% |
| 50-Day Moving Average | 11.67 |
| 200-Day Moving Average | 11.33 |
| Relative Strength Index (RSI) | 40.08 |
| Average Volume (20 Days) | 3,994 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, BioSyent had revenue of CAD 39.51 million and earned 8.26 million in profits. Earnings per share was 0.71.
| Revenue | 39.51M |
| Gross Profit | 30.89M |
| Operating Income | 10.71M |
| Pretax Income | 11.13M |
| Net Income | 8.26M |
| EBITDA | 11.18M |
| EBIT | 10.71M |
| Earnings Per Share (EPS) | 0.71 |
Balance Sheet
The company has 20.36 million in cash and 942,232 in debt, giving a net cash position of 19.42 million or 1.72 per share.
| Cash & Cash Equivalents | 20.36M |
| Total Debt | 942,232 |
| Net Cash | 19.42M |
| Net Cash Per Share | 1.72 |
| Equity (Book Value) | 37.60M |
| Book Value Per Share | 3.34 |
| Working Capital | 25.55M |
Cash Flow
In the last 12 months, operating cash flow was 11.97 million and capital expenditures -59,936, giving a free cash flow of 11.91 million.
| Operating Cash Flow | 11.97M |
| Capital Expenditures | -59,936 |
| Free Cash Flow | 11.91M |
| FCF Per Share | 1.06 |
Margins
Gross margin is 78.18%, with operating and profit margins of 27.10% and 20.90%.
| Gross Margin | 78.18% |
| Operating Margin | 27.10% |
| Pretax Margin | 28.16% |
| Profit Margin | 20.90% |
| EBITDA Margin | 28.29% |
| EBIT Margin | 27.10% |
| FCF Margin | 30.15% |
Dividends & Yields
This stock pays an annual dividend of 0.20, which amounts to a dividend yield of 1.79%.
| Dividend Per Share | 0.20 |
| Dividend Yield | 1.79% |
| Dividend Growth (YoY) | 11.43% |
| Years of Dividend Growth | 3 |
| Payout Ratio | 27.48% |
| Buyback Yield | 2.47% |
| Shareholder Yield | 4.26% |
| Earnings Yield | 6.54% |
| FCF Yield | 9.44% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioSyent has an Altman Z-Score of 16.17 and a Piotroski F-Score of 5.
| Altman Z-Score | 16.17 |
| Piotroski F-Score | 5 |